Back to mobile site
Get it on Google Play

Zymeworks receives FDA fast track designation for ovarian cancer drug

March 30, 2026 6:00 AM EDT Send to a Friend
Zymeworks Inc. (NASDAQ: ZYME) announced that the U.S. Food and Drug Administration has granted Fast Track designation to ZW191, an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login